Immunogenicity and reactogenicity of a 13-valent-pneumococcal conjugate vaccine administered at 2, 4, and 12 months of age: a double-blind randomized active-controlled trial
Snape, Matthew D., Klinger, Chaam L., Daniels, Elvis D., John, Tessa M., Layton, Helen, Rollinson, Llinos, Pestridge, Sarah, Dymond, Sandra, Galiza, Eva, Tansey, Susan, Scott, Daniel A., Baker, Sherryl A., Jones, Thomas R., Yu, Ly-Mee, Gruber, William C., Emini, Emilio A., Faust, Saul N., Finn, Adam, Heath, Paul T. and Pollard, Andrew J. (2010) Immunogenicity and reactogenicity of a 13-valent-pneumococcal conjugate vaccine administered at 2, 4, and 12 months of age: a double-blind randomized active-controlled trial. Pediatric Infectious Disease Journal, 29, (12), e80-90. (doi:10.1097/INF.0b013e3181faa6be). (PMID:21155091).
Full text not available from this repository.
Background: A 2-, 4-, and 12-month schedule of a novel 13-valent-pneumococcal conjugate vaccine (PCV13), containing serotype 1, 3, 4, 5, 6A, 6B 7F, 9V, 14, 18C, 19A, 19F, and 23F polysaccharides individually conjugated to CRM197 was evaluated in a randomized, double-blind, controlled infant study.
Methods: Two hundred eighty-six healthy infants received PCV13 or the 7-valent-pneumococcal conjugate vaccine (PCV7) at 2, 4, and 12 months of age, alongside a serogroup C meningococcal (MenC) vaccine (2 and 4 months of age), DTaP-IPV-Hib (2, 3, and 4 months), and a Hib-MenC vaccine (12 months). Specific antibody responses were assessed at age 5, 12, and 13 months.
Results: At 13 months of age, >97% of PCV13 recipients had pneumococcal serotype-specific serum IgG concentrations ≥0.35 μg/mL for each vaccine serotype except serotype 3 (88.2%), and at least 93% of PCV13 recipients had OPA titers ≥1:8 for each serotype. At 5 months, 110/114 (96.5%) of PCV13 recipients and 100/102 (98.0%) of PCV7 recipients had serum anti-PRP (Hib) IgG concentration ≥0.15 μg/mL (difference, 1.5%; CI, −7.1%–3.7%), while 119/120 (99.2%) and 117/118 (99.2%), respectively, had MenC serum bactericidal assay titers of ≥1:8. All PCV13 recipients and 110/113 (97.3%) of PCV7 recipients had IgG concentrations against fimbrial agglutinogens of ≥2.2 EU/mL; IgG concentrations for the remaining pertussis antigens were ≥5 EU/mL for all participants. Local reactions and systemic events were similar in the PCV13 and PCV7 groups.
Conclusions: A 2-, 4-, and 12-month course of PCV13 was immunogenic for all 13 vaccine serotypes and was well tolerated.
|Subjects:||Q Science > QR Microbiology > QR180 Immunology
Q Science > QR Microbiology > QR355 Virology
R Medicine > RB Pathology
|Divisions:||University Structure - Pre August 2011 > School of Medicine > Infection, Inflammation and Repair
|Date Deposited:||24 Feb 2011 14:17|
|Last Modified:||01 Jun 2011 07:54|
|Contributors:||Snape, Matthew D. (Author)
Klinger, Chaam L. (Author)
Daniels, Elvis D. (Author)
John, Tessa M. (Author)
Layton, Helen (Author)
Rollinson, Llinos (Author)
Pestridge, Sarah (Author)
Dymond, Sandra (Author)
Galiza, Eva (Author)
Tansey, Susan (Author)
Scott, Daniel A. (Author)
Baker, Sherryl A. (Author)
Jones, Thomas R. (Author)
Yu, Ly-Mee (Author)
Gruber, William C. (Author)
Emini, Emilio A. (Author)
Faust, Saul N. (Author)
Finn, Adam (Author)
Heath, Paul T. (Author)
Pollard, Andrew J. (Author)
|RDF:||RDF+N-Triples, RDF+N3, RDF+XML, Browse.|
Actions (login required)